Brown, A <br/><br/>
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.  [electronic resource] 

 -  Journal of viral hepatitis  05 2018 
 - 457-464 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2893 
<br/><br/><label>Standard No.: </label>10.1111/jvh.12801  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Amides<br/>Antiviral Agents--administration & dosage<br/>Benzofurans--administration & dosage<br/>Carbamates<br/>Cyclopropanes<br/>Drug Therapy, Combination--adverse effects<br/>Drug-Related Side Effects and Adverse Reactions--epidemiology<br/>Female<br/>Genotype<br/>Hepacivirus--classification<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Imidazoles--administration & dosage<br/>Male<br/>Middle Aged<br/>Quinoxalines--administration & dosage<br/>Ribavirin--administration & dosage<br/>Sulfonamides<br/>Sustained Virologic Response<br/>Treatment Outcome<br/>Young Adult